Experiment: give an antioxidant with the CXCR4 antagonist — if the drug stops working, the niche is a redox buffer and not a hiding place
also called antioxidant rescue of CXCR4 blockade · redox versus retention test
There are two competing explanations for why blocking the CXCR4 receptor hurts this leukaemia: either it evicts the cells from a protective spot in the marrow, or it removes a chemical support that keeps the cells from being damaged by their own metabolism. One cheap experiment tells them apart — add an antioxidant, and if the drug stops working, it was the chemical support.
The same thing, for a scientist
Two independent genetic experiments in MLL-AF9/MLL::AF9 models converge on oxidative stress. Deleting **Cxcl12** from Prx1+ mesenchymal cells caused ROS accumulation and DNA damage in leukaemia stem cells and impaired serial transplantation, **and the defect was attenuated by antioxidant therapy** [E1]. Deleting **Cxcr4** in a CRISPR screen eradicated leukaemia **without impairing marrow homing**, with CXCL12 dispensable in recipients, and loss of CXCR4 signalling caused **oxidative stress and differentiation** in vivo [E2]. Both point away from retention and towards redox. The test: treat KMT2A-rearranged models with a CXCR4 antagonist with and without N-acetylcysteine or an equivalent antioxidant, and measure whether antioxidant co-treatment **rescues** the leukaemia. A rescue means the antagonist's mechanism is redox and its rational partners are oxidative stressors, not mobilisation-timed cytotoxics. No rescue means the retention model survives and the drug should be scheduled as a mobilising agent - which is how the one paediatric trial used it, to modest effect (`trial-poe-10-03-plerixafor-paediatric`).
Design
Arms. Plerixafor alone; plerixafor plus N-acetylcysteine; NAC alone; vehicle. Repeat with a second, structurally unrelated antioxidant (for example a mitochondria-targeted agent) to guard against NAC's well-known off-target effects on thiol biology generally.
Models. In vitro on stroma first, then a KMT2A-rearranged patient-derived xenograft, with at least one KMT2A::AFF1 infant B-ALL PDX, because the human retention data are entirely lymphoid and infant while the redox data are entirely murine and myeloid.
Readouts. Leukaemia burden and survival; mitochondrial and cytosolic ROS; reduced/oxidised glutathione ratio; gamma-H2AX as a DNA-damage readout matching 1; and circulating blast count as a mobilisation readout, so that mobilisation and efficacy can be dissociated. That dissociation is the point of the experiment: POE 10-03 showed mobilisation without proportionate benefit, and this design measures both in the same animal.
Controls. A CXCR4-low line as negative control. Cytarabine plus antioxidant as a comparator, since if the antioxidant rescues everything the result is uninformative about CXCR4 specifically.
Why it is worth doing before any further trial
The CXCR4 hypothesis in this disease has a strong preclinical case, no clinical test in the right population, and a registry of trials that closed for want of patients (ana-cxcr4-directed-trials-kmt2a-infant). Accrual in infant leukaemia is precious. Before anyone spends it, it is worth knowing whether the drug is being scheduled according to the right mechanism.
If the redox model is right, the current schedule — antagonist four hours before cytotoxic chemotherapy, to catch a mobilisation window — is aimed at the wrong thing, and continuous exposure combined with an oxidative stressor would be the design. That is a difference a $20,000 mouse experiment can settle and a phase 1 cannot.
| design | four-arm in vivo study (plerixafor; plerixafor + N-acetylcysteine; NAC alone; vehicle) repeated with a second structurally unrelated antioxidant, in KMT2A-rearranged PDX including at least one infant KMT2A::AFF1 B-ALL model, preceded by a stromal co-culture version |
|---|---|
| readout | leukaemia burden and survival; mitochondrial and cytosolic ROS; GSH/GSSG ratio; gamma-H2AX; AND circulating blast count as an independent mobilisation readout so that mobilisation and efficacy can be dissociated in the same animal |
| controls | CXCR4-low line as negative control; cytarabine plus antioxidant as a specificity comparator; all lines verified in Cellosaurus by accession; any non-KMT2A comparator screened for pathway-equivalent lesions (PICALM::MLLT10, NUP98 fusions, NPM1c, other HOXA/MEIS1 drivers) |
| cost tier | med |
| timeline | 3-4 months including PDX expansion |
| decision rule | antioxidant rescue implies the antagonist acts on a redox axis and should be partnered with oxidative stressors under continuous exposure; no rescue implies the retention model and supports mobilisation-timed scheduling |
| why before a trial | accrual in infant leukaemia is scarce and two CXCR4 trials in paediatric leukaemia have already closed for want of patients; the scheduling question should be settled in mice |
tests hypotheses
[ "hyp-niche-remodelling-precedes-relapse-kmt2a" ]
- A positive result would imply that antioxidant-containing supportive care could antagonise a niche-directed drug, which is an uncomfortable clinical interaction to discover after a trial rather than before it.
- Antioxidants have themselves been reported to promote tumour progression in other cancers, so a rescue arm is not a benign control and the animals need careful monitoring.
- Both anchoring experiments are genetic and murine and myeloid; a null result could mean the model is wrong rather than the mechanism.
- Does pharmacological CXCR4 antagonism reproduce the genetic deletion phenotype at all? Both anchoring results are genetic, and this is the experiment's largest assumption.
- Is N-acetylcysteine the right antioxidant, given its broad thiol effects and poor intracellular penetration at achievable doses?
- If the antioxidant rescues both plerixafor and cytarabine, the result is uninformative about CXCR4 - how large a specificity margin would be convincing?
- Could the same design be run with natalizumab, to ask whether integrin-mediated niche support is also redox-based?
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In an MLL::AF9 AML model, CXCL12 from Prx1-positive mesenchymal cells maintains leukaemia stem cells by modulating energy metabolism and redox balance; deletion of Cxcl12 leads to accumulation of reactive oxygen species and DNA damage in LSCs and impairs their ability to perpetuate leukaemia in transplantation, and that defect is ATTENUATED BY ANTIOXIDANT THERAPY.
The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells · Vinado AC, Calvo IA, Cenzano I, Olaverri D, Cocera M, San Martin-Uriz P, Romero JP, Vilas-Zornoza A, et al. · Leukemia 2022What this evidence cannot show
Mouse, myeloid, genetic ligand deletion rather than pharmacological receptor blockade - and the two are not equivalent, which is the central assumption this experiment makes and should state. Prx1-cre is a broad mesenchymal driver. Antioxidant rescue is reported as attenuation, not abolition. Read: abstract only.
Evidence that argues against this (1)
- In the same driver, a CRISPR screen found CXCL12 DISPENSABLE for leukaemia development in recipient mice while CXCR4 was a top dependency, so the ligand-deletion phenotype on which this rescue logic rests is not reproduced as a requirement in that system. If the ligand is dispensable, an antioxidant rescue of ligand deletion may not predict anything about receptor blockade. Read: abstract only. Ramakrishnan R et al. 2020
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
A CRISPR-Cas9 cell-surface screen in syngeneic MLL-AF9 AML identified CXCR4 as a top regulator of growth and survival; Cxcr4 deletion eradicated leukaemia in vivo WITHOUT impairing homing to bone marrow, mutant-receptor experiments showed signalling is what is required, and loss of CXCR4 signalling led to OXIDATIVE STRESS and differentiation in vivo.
CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia · Ramakrishnan R, Pena-Martinez P, Agarwal P, Rodriguez-Zabala M, Chapellier M, Hogberg C, Eriksson M, Yudovich D, et al. · Cell Reports 2020What this evidence cannot show
Mouse, myeloid, genetic deletion of the receptor rather than pharmacological antagonism; plerixafor blocks ligand binding and does not remove the receptor, so a genetic phenotype may not be reproduced pharmacologically. This is a real threat to the experiment's interpretability and is why the design includes a mobilisation readout alongside efficacy. Read: abstract only.
Evidence that argues against this (1)
- The human data in the right disease support a retention mechanism that this experiment is designed to test against: primary infant MLL-rearranged ALL is differentially protected by stroma, protection is conferred by stroma-produced soluble factors alone, and AMD3100 markedly enhanced drug efficacy in xenograft - a pattern consistent with chemokine-mediated protection rather than a purely cell-intrinsic redox requirement. Read: abstract only. Sison EA et al. 2013
prediction 3: antioxidant co-treatment rescues the leukaemia from CXCR4 blockade
distinguishes the redox model from the retention model of CXCR4 dependence
the experiment this graph already proposes for the redox arm of the axis